Previous Next

ARCHIVE

№2' 2021

OBSTETRICS AND GYNECOLOGY

International Medical Journal, Vol. 27., Iss. 2, 2021, P. 52−56.

DOI (https://doi.org/10.37436/2308-5274-2021-2-9)

COMPARATIVE ASSESSMENT OF BIOCHEMICAL AND HORMONAL PROFILES OF WOMEN WITH POLYCYSTIC OVARY SYNDROME

Kharkiv National Medical University, Ukraine

Polycystic ovary syndrome is not considered as an independent disease, but as a phenomenon that combines a number of symptoms and has common clinical and biochemical manifestations. It is accompanied by ovarian dysfunction, increased secretion of androgens, estrogens, insulin, pathology of the pituitary gland and hypothalamus. This is a clinical syndrome in which there are found many 2−6−millimeter or larger follicular cysts containing atretic follicles in the ovary. The ovaries are usually enlarged and have a thickened and smoothed protein shell. To comparatively analyze the hormonal and biochemical parameters for the patients suffered from polycystic ovary syndrome with and without metabolic syndrome, 140 women were examined. The study of insulin resistance in such patients deserved a special attention, as its development is closely related to hyperandrogenemia, i.e. the syndrome direct cause. Hormonal studies of the blood of women with polycystic ovary syndrome showed that the changes in hormonal background were unidirectional, regardless of the presence of metabolic disorders. No significant differences, with the exception of prolactin levels, in the groups of patients with and without metabolic syndrome were detected. The data obtained indicate the presence of ovarian hyperandrogenism, which leads to a disorder of the central and peripheral mechanisms of regulation of steroidogenesis. Hormonal secretion and biochemical parameters of patients depend on the clinical form of the disease. Moderate hyperprolactinemia, decreased somatomedin−C levels on the background of insulin resistance were observed in the patients with metabolic disorders, and moderate hyperandrogenism was found in the patients without metabolic changes. Both groups were characterized by an increased ratio of luteinizing and follicle−stimulating hormones, which were more pronounced in women with metabolic syndrome.

Key words: polycystic ovary syndrome, biochemical and hormonal profiles, steroidogenesis.

REFERENCES

1. Rasprostranennost' i klinicheskaya kartina sindroma polikistoznykh yaichnikov v populyatsii Moskvy / I. I. Dedov i dr. // Problemy endokrinologii. 2010. T. 56, № 4. S. 3−8.

2. Kozub N. I. Polikistoz yaichnikov // Mezhdunarod. meditsinskii zhurn. 1998. № 4. S. 67−70.

3. Nazarenko T. A. Sindrom polikistoznykh yaichnikov: sovremennyi podkhod k diagnostike i lecheniyu besplodiya. 2−e izd. M.: MED−press−inform, 2008. S. 21−51.

4. Lechenie metabolicheskogo sindroma u patsientok s sindromom polikistoznykh yaichnikov / V. K. Dorozhkin i dr. // Voprosy upravleniya v razvitii sistemy pervichnoi mediko−sanitarnoi pomoshchi: aktual'nye voprosy gematologii: sb. statei nauch.−prakt. konf. Samara, 2017. S. 104−105.

5. Geneticheskie aspekty formirovaniya sindroma polikistoznykh yaichnikov / A. A. Naidukova, E. K. Kaprina, A. E. Donnikov, G. E. Chernukha // Akusherstvo i ginekologiya. 2016. № 3. S. 16−22.

6. Yen S. S. C. Chronic anovuletion causet by peripheral endocrine disorders // Reproductive endocrinology: physiology, pathophysiology, and clinical managment. Philadelphia: Saunders W.B., 1986. P. 462−487.

7. Visfatin in overweight/obesity, type 2 diabetes mellitus, insulin resistance, metabolic syndrome and cardiovascular diseases: a meta−analysis and systemic review / Y. H. Chang et al. // Diabetes Metab. Res. Rev. 2020. T. 27, № 6. P. 515−527. doi: https://doi.org/10.1002/dmrr.1201

8. Dağ Z. Ö., Dilbaz B. J. Impact of obesity on infertility in women // Turk. Ger. Gynecol. Assoc. 2019. T. 16, № 2. P.111−117.

9. Agacayak E., Tunc S. Y., Sak S. Levels of neopterin and other inflammatory markers in obese and non−obese patients with polycystic ovary syndrome // Med. Sci. Monit. 2015. № 21. P. 2446−2455. doi: https://doi.org/10.12659/msm.894368

10. Endocrine and clinical effects of myoinositol administration in polycystic ovary syndrome. A randomized study / P. G. Artini et al. // Gynecol. Endocrinol. 2020. T. 29, № 4. P. 375−379.

11. Shifrina Yu. O., Drapkina O. M., Ivashkin V. T. Molekulyarnye aspekty insulinorezistentnosti // Rossiiskie meditsinskie vesti. 2012. № 3. S. 17−25.

12. Further investigation in europeans of susceptibility variants for olycystic ovary syndrome discovered in genome−wide association studies of Chinese individuals / M. A. Brower et al. // J. Clin. Endocrinol. Metab. 2015. T. 100, № 1. P. 182−186. doi: https://doi.org/10.1210/jc.2014−2689

13. A methodological and functional proteomic approach of human follicular fluid en route for oocyte quality evaluation / L. Bianchi et al. // J. Proteomics. 2019. № 90. P. 61−76. doi: https://doi.org/10.1016/j.jprot.2013.02.025

14. Nikolaenkov I. P., Potin V. V., Tarasova M. A. Antimyullerov gormon i sindrom polikistoznykh yaichnikov // Zhurn. akusherstva i zhenskikh boleznei. 2013. T. 62, № 6. S. 55−59.

15. Dai G., Lu G. Different protein expression patterns associated with polycystic ovary syndrome in human follicular fluid during controlled ovarian hyperstimulation // Reprod. Fertil. Dev. 2012. T. 24, № 7. P. 893−904. doi: https://doi.org/10.1071/rd11201